21.12.2025 17:40
Turkish scientist Gizem Karslı Uzunbaş, who works at the Broad Institute affiliated with MIT and Harvard University, has achieved significant success in the global scientific community with a drug she developed for the treatment of lung cancer. After approximately six years of meticulous scientific research, the drug candidate has received approval from the U.S. Food and Drug Administration (FDA). This approval means that the drug can officially proceed to the clinical trial phase in humans.
Turkish scientist Gizem Karslı Uzunbaş has signed a promising drug for lung cancer treatment with her work at the Broad Institute, affiliated with the world's most prestigious research centers, MIT and Harvard University. The drug candidate, the product of approximately 6 years of effort, has qualified for clinical trial phase after receiving approval from the FDA.
INTERNATIONAL APPROVAL FOR 6 YEARS OF EFFORT
In the study conducted by Gizem Karslı Uzunbaş and her team, the cellular mechanisms that lead to lung cancer were directly targeted. Thus, a more controlled, effective, and innovative treatment approach was developed. The successful results obtained in laboratory and pre-clinical stages paved the way for the drug's evaluation by the FDA.
The FDA approval indicates that the drug meets the criteria for safety, efficacy, and scientific adequacy, and clinical studies to be conducted on humans are planned to be initiated in the upcoming period.
THE CANCER TYPE CAUSING THE MOST DEATHS IN THE WORLD
This new treatment approach developed for lung cancer, one of the cancer types causing the most deaths worldwide, is expected to:
Provide an alternative to existing treatments,
Offer new hope for treatment-resistant cases,
Reduce the rate of side effects.
A TURKISH SIGNATURE IN GLOBAL SCIENCE
The success achieved by Gizem Karslı Uzunbaş once again highlights the impact of Turkish scientists in the international health and biotechnology fields. This study, which received FDA approval, is considered more than an individual success; it is seen as a reflection of long-term scientific effort, disciplined research, and the global impact of Turkish academic accumulation.